A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P)—an opt-in policy implemented in ...

Learn about the key changes to Medicare prescription drug coverage in 2026, including a new out-of-pocket cap, insulin cost limits, and a payment plan option.

Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic ...

In a move to make healthcare more affordable, a new Medicare rule will limit insulin costs to $35 monthly starting in 2026. This change, rooted in the Inflation Reduction Act of 2022, ensures that no ...

Medicare and Medicaid costs are expected to more than double between fiscal year 2012 and FY 2022, according to a March budget report from the Congressional Budget Office. The budget projections, ...

CMS’ Part D Senior Savings Model effectively increased insulin use while reducing out-of-pocket costs among Medicare beneficiaries, according to a RAND report published Sept. 22. The program also ...

Nearly 9 million Medicare seniors use the drugs, which treat conditions such as diabetes, heart disease, cancer and autoimmune disorders Total savings for Medicare Part D enrollees are expected to ...

Farxiga can cost between $400 and $600 without insurance, depending on the pharmacy and whether a person buys the brand drug or the generic. Whether Medicare can pay a share of this cost depends on ...

TEAM may encourage hospitals to improve the quality of the care their patients receive after being discharged. But it also risks further burdening family caregivers. I ...